


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on April 20, 2009.



Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 CFR
§1.825(a) THROUGH (c)
Patent Application
Docket No. C.R.116
Serial No. 10/579,113

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Richard Joseph Fagan, Andrew Robert Davids, Christopher Benjamin Phelps, Christine Power, Ursula Boschert, Yolande Chvatchko
Serial No. : 10/579,113
Filed : May 11, 2006
Confirm. No. : 1499
For : Cytokine Antagonist Molecules

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification of Defective Response dated March 26, 2009, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: